Compare Aventis Pharma with AJANTA PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SANOFI INDIA vs AJANTA PHARMA - Comparison Results

SANOFI INDIA     Change

Sanofi India (the erstwhile Aventis Pharma), the 60% subsidiary of Sanofi-Aventis SA, France, is one of the largest pharma MNCs in India with a turnover of over Rs 13.2 bn in CY11. Domestic sales constituted 81% of total sales in CY11 and exports con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SANOFI INDIA AJANTA PHARMA SANOFI INDIA/
AJANTA PHARMA
 
P/E (TTM) x 35.4 21.4 165.1% View Chart
P/BV x 6.2 3.8 164.1% View Chart
Dividend Yield % 1.4 0.9 150.7%  

Financials

 SANOFI INDIA   AJANTA PHARMA
EQUITY SHARE DATA
    SANOFI INDIA
Dec-18
AJANTA PHARMA
Mar-19
SANOFI INDIA/
AJANTA PHARMA
5-Yr Chart
Click to enlarge
High Rs6,8401,422 481.1%   
Low Rs4,630898 515.8%   
Sales per share (Unadj.) Rs1,203.1233.5 515.2%  
Earnings per share (Unadj.) Rs165.344.0 375.9%  
Cash flow per share (Unadj.) Rs209.952.2 402.4%  
Dividends per share (Unadj.) Rs84.009.00 933.3%  
Dividend yield (eoy) %1.50.8 188.7%  
Book value per share (Unadj.) Rs963.6255.1 377.8%  
Shares outstanding (eoy) m23.0388.02 26.2%   
Bonus/Rights/Conversions -BB-  
Price / Sales ratio x4.85.0 96.0%   
Avg P/E ratio x34.726.4 131.6%  
P/CF ratio (eoy) x27.322.2 122.9%  
Price / Book Value ratio x6.04.5 130.9%  
Dividend payout %50.820.5 248.3%   
Avg Mkt Cap Rs m132,078102,081 129.4%   
No. of employees `0003.36.8 48.5%   
Total wages/salary Rs m4,0684,307 94.4%   
Avg. sales/employee Rs Th8,393.83,022.6 277.7%   
Avg. wages/employee Rs Th1,232.4633.4 194.6%   
Avg. net profit/employee Rs Th1,153.0569.1 202.6%   
INCOME DATA
Net Sales Rs m27,70820,554 134.8%  
Other income Rs m897211 425.5%   
Total revenues Rs m28,60520,765 137.8%   
Gross profit Rs m6,2355,664 110.1%  
Depreciation Rs m1,027721 142.5%   
Interest Rs m712 60.3%   
Profit before tax Rs m6,0985,143 118.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2,2921,273 180.0%   
Profit after tax Rs m3,8063,870 98.4%  
Gross profit margin %22.527.6 81.7%  
Effective tax rate %37.624.8 151.8%   
Net profit margin %13.718.8 73.0%  
BALANCE SHEET DATA
Current assets Rs m15,92211,812 134.8%   
Current liabilities Rs m6,2353,776 165.1%   
Net working cap to sales %35.039.1 89.4%  
Current ratio x2.63.1 81.6%  
Inventory Days Days6477 82.2%  
Debtors Days Days2182 25.6%  
Net fixed assets Rs m7,53914,398 52.4%   
Share capital Rs m230175 131.1%   
"Free" reserves Rs m21,96222,277 98.6%   
Net worth Rs m22,19222,452 98.8%   
Long term debt Rs m07 0.0%   
Total assets Rs m29,83926,962 110.7%  
Interest coverage x872.1444.3 196.3%   
Debt to equity ratio x00 0.0%  
Sales to assets ratio x0.90.8 121.8%   
Return on assets %12.814.4 88.8%  
Return on equity %17.217.2 99.5%  
Return on capital %27.523.0 119.9%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m7,58710,682 71.0%   
Fx outflow Rs m7,1452,102 339.9%   
Net fx Rs m4428,580 5.2%   
CASH FLOW
From Operations Rs m3,7393,748 99.8%  
From Investments Rs m-731-2,228 32.8%  
From Financial Activity Rs m-1,972-1,475 133.7%  
Net Cashflow Rs m1,03645 2,292.0%  

Share Holding

Indian Promoters % 0.0 73.8 -  
Foreign collaborators % 60.4 0.0 -  
Indian inst/Mut Fund % 14.4 1.6 929.0%  
FIIs % 14.6 7.6 192.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.5 17.0 61.8%  
Shareholders   15,184 20,968 72.4%  
Pledged promoter(s) holding % 0.0 4.4 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SANOFI INDIA With:   PLETHICO PHARMA  BIOCON   FULFORD INDIA  DR. DATSONS LABS  WOCKHARDT  

Compare SANOFI INDIA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 93 Points Higher; Oil & Gas and Realty Stocks Witness Buying(Closing)

Indian share markets traded on a volatile note throughout the day and ended marginally higher. Sectoral indices ended on a mixed note with stocks in the oil & gas sector.

Related Views on News

AJANTA PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 8.4% (Quarterly Result Update)

Aug 2, 2019 | Updated on Aug 2, 2019

For the quarter ended June 2019, AJANTA PHARMA has posted a net profit of Rs 1 bn (up 8.4% YoY). Sales on the other hand came in at Rs 6 bn (up 19.8% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

SANOFI INDIA Announces Quarterly Results (1QFY20); Net Profit Down 2.2% (Quarterly Result Update)

Jul 31, 2019 | Updated on Jul 31, 2019

For the quarter ended June 2019, SANOFI INDIA has posted a net profit of Rs 974 m (down 2.2% YoY). Sales on the other hand came in at Rs 7 bn (up 9.4% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

AJANTA PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Jun 24, 2019 | Updated on Jun 24, 2019

Here's an analysis of the annual report of AJANTA PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of AJANTA PHARMA. Also includes updates on the valuation of AJANTA PHARMA.

SANOFI INDIA Announces Quarterly Results (4QFY19); Net Profit Up 12.6% (Quarterly Result Update)

May 8, 2019 | Updated on May 8, 2019

For the quarter ended March 2019, SANOFI INDIA has posted a net profit of Rs 929 m (up 12.6% YoY). Sales on the other hand came in at Rs 7 bn (up 16.1% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

AJANTA PHARMA Announces Quarterly Results (4QFY19); Net Profit Down 5.9% (Quarterly Result Update)

May 3, 2019 | Updated on May 3, 2019

For the quarter ended March 2019, AJANTA PHARMA has posted a net profit of Rs 889 m (down 5.9% YoY). Sales on the other hand came in at Rs 5 bn (down 2.9% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

More Views on News

Most Popular

My 3 Best Small-cap Stocks to Get Rich in this Market Rebound(Profit Hunter)

Oct 14, 2019

This is once in a decade opportunity to make a killing from smallcap rebound.

Finally, Is the Share Price of Yes Bank Ready for a Rebound?(The 5 Minute Wrapup)

Oct 7, 2019

Here's what every individual investor must know about Yes Bank...

Rebound Riches Could be Yours With These Stocks(Profit Hunter)

Oct 4, 2019

The secret to multibagger is not big businesses, but great managements... Here's how to find them to make the most of once in a decade rebound opportunity.

The One Stock I Like in this Market(The 5 Minute Wrapup)

Oct 10, 2019

There are rare periods in markets when you get good quality stocks at attractive valuations. Is this one such period?

5 Smart Money Stocks to Profit from the Market Rebound(The 5 Minute Wrapup)

Oct 11, 2019

Now is the time to put money in these 5 stocks to take advantage of the recovery in the economy and the markets.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

SANOFI INDIA SHARE PRICE


Oct 16, 2019 (Close)

TRACK SANOFI INDIA

  • Track your investment in SANOFI INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SANOFI INDIA 8-QTR ANALYSIS

COMPARE SANOFI INDIA WITH

MARKET STATS